Marine-Derived Natural Compounds for the Treatment of Parkinson's Disease

• Published in: Marine drugs Vol. 17; no. 4; p. 221
• Main Authors: Huang, Chunhui, Zhang, Zaijun, Cui, Wei
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11-04-2019; MDPI
• Subjects: Aetiology; Aggregation; Amine oxidase (flavin-containing); Animals; Antioxidants; Apoptosis; Aquatic Organisms; Bacteria; Biological Factors - isolation & purification; Biological Factors - pharmacology; Biological Factors - therapeutic use; Brain-derived neurotrophic factor; Chemical compounds; Clinical trials; Clinical Trials as Topic; Degeneration; Dopamine; Dopamine receptors; Dopaminergic Neurons - cytology; Dopaminergic Neurons - drug effects; Dopaminergic Neurons - pathology; Drugs; Etiology; Health services; Humans; Inflammation; Insomnia; marine-derived natural compounds; Metabolism; Metabolites; Mitochondria; Mitochondria - drug effects; Mitochondria - pathology; Movement disorders; Natural products; Neurodegeneration; Neurodegenerative diseases; Neurons; Neuroprotection; neuroprotective; Neuroprotective Agents - isolation & purification; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Neurotoxicity; Oxidative stress; Oxidative Stress - drug effects; Parkinson Disease - drug therapy; Parkinson Disease - pathology; Parkinson's disease; Parkinsons disease; Proteins; Reactive oxygen species; Review; Synuclein; α-synuclein; clinical trials; marine-derived natural compounds; neuroprotective; Parkinson’s disease; oxidative stress; α-synuclein
• ISSN: 1660-3397; 1660-3397
• DOI: 10.3390/md17040221

Parkinson's disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons, leading to the motor dysfunctions of patients. Although the etiology of PD is still unclear, the death of dopaminergic neurons during PD progress was revealed to be associated with the abnormal aggregation of α-synuclein, the elevation of oxidative stress, the dysfunction of mitochondrial functions, and the increase of neuroinflammation. However, current anti-PD therapies could only produce symptom-relieving effects, because they could not provide neuroprotective effects, stop or delay the degeneration of dopaminergic neurons. Marine-derived natural compounds, with their novel chemical structures and unique biological activities, may provide anti-PD neuroprotective effects. In this study, we have summarized anti-PD marine-derived natural products which have shown pharmacological activities by acting on various PD targets, such as α-synuclein, monoamine oxidase B, and reactive oxygen species. Moreover, marine-derived natural compounds currently evaluated in the clinical trials for the treatment of PD are also discussed.